Biological Testing Facility

SOL #: 75N94026R00005Solicitation

Overview

Buyer

Health And Human Services

National Institutes Of Health

NATIONAL INSTITUTES OF HEALTH NICHD

BETHESDA, MD, 20817, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in the Physical (541715)

PSC

Health R&D Services; Health Care Services; Applied Research (AN12)

Set Aside

No set aside specified

Original Source

https://sam.gov/opp/5e2c13a238e14f5f985ae675502abb58/view

Timeline

Posted

Mar 27, 2026

Last Updated

Apr 28, 2026

Submission Deadline

May 28, 2026, 8:00 PM

Qualification Details

Fit reasons

NAICS alignment with historical contract wins in similar service areas.
Scope strongly matches core technical capabilities and delivery model.

Risks

Past performance thresholds may require one additional teaming partner.
Potential clarification needed on staffing minimums before bid/no-bid.

Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The National Institutes of Health (NIH), specifically the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has issued a Solicitation for a Biological Testing Facility (BTF). This Indefinite-Delivery, Indefinite-Quantity (IDIQ) contract aims to support research and development for fertility management and reproductive health, including contraceptive agents and therapies. The competition is Unrestricted / Full and Open. Proposals are due May 28, 2026, by 4:00 PM EST.

Scope of Work

The BTF will provide comprehensive preclinical development services, bridging discovery to Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications. Key requirements include:

Conducting in vitro enzymatic and cell-based assays, and in vivo studies for anti-fertility assessments, endocrine activity, toxicity, formulation, and stability testing.
Performing Absorption Distribution Metabolism Excretion (ADME) and Drug Metabolism Pharmacokinetics (DMPK) profiling.
Providing biological safety and efficacy evaluations for new chemical compounds, delivery systems, and devices.
Offering preclinical R&D services such as bioinformatics, efficacy, safety/toxicology, formulation, and animal care, ensuring compliance with the Animal Welfare Act and Public Health Service Policy.
Managing databases, data, documents, products, specimens, and inventory.
Assisting with clinical study report preparation and IND application documentation and filing support.

Contract Details

Contract Type: Indefinite-Delivery, Indefinite-Quantity (IDIQ), cost-reimbursement.
Period of Performance: Anticipated 7-year ordering period, from September 30, 2026, through September 29, 2033.
Estimated Value: Minimum $100,000; Maximum $49,000,000.
Set-Aside: Unrestricted / Full and Open Competition (Not set-aside for small business).
NAICS Code: 541715 (Health R&D Services; Health Care Services; Applied Research).

Submission & Evaluation

Proposals must be submitted electronically via the eCPS website by May 28, 2026, at 4:00 PM EST. Questions are due by May 1, 2026, via email. Evaluation will prioritize technical factors, which are significantly more important than cost/price. Technical factors include experience, compliance, project management, a Data Management and Sharing Plan, and a Vertebrate Animal Section (VAS) if applicable. Offerors must be registered in SAM.